Literature DB >> 10770766

Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.

P J de Vries1, N N Bich, H Van Thien, L N Hung, T K Anh, P A Kager, S H Heisterkamp.   

Abstract

Combinations of artemisinin and quinine for uncomplicated falciparum malaria were studied. A total of 268 patients were randomized to 7 days of quinine at 10 mg/kg of body weight three times a day (Q) or to artemisinin at 20 mg/kg of body weight followed by 3 (AQ3) or 5 (AQ5) days of quinine. Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, respectively (P < 0.001). Recrudescence was associated with shorter parasite clearance time (PCT) and longer treatment after the blood smear had become negative (eradication time). However, classification of patients to outcome-recrudescence or radical cure-was correct in only 77% of patients. The population kinetics of the parasitemia was estimated with nonlinear mixed-effect models. Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5.1 h; 95% confidence interval [CI], 4.9 to 5.2 h) than after quinine (8.0 h [95% CI, 7.5 to 8.3 h]). Attempts to simulate the initial increase of the parasitemia did not result in better models with a biologically plausible interpretation. Recrudescence was associated with slower parasite clearance and a higher simulated terminal parasitemia (P(term)). The classification of patients to outcome groups based on P(term) was correct in 78% of patients. The data suggest that parasite strains with reduced sensitivity to quinine are prevalent in Vietnam, with slower parasite clearance and consequent recrudescence. A single dose of artemisinin induces rapid parasite reduction and lowers the value of P(term), but to prevent recrudescence, this should be followed by quinine for at least 3 days after parasite clearance, or 5 days in total.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770766      PMCID: PMC89859          DOI: 10.1128/AAC.44.5.1302-1308.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Comparative effectiveness of artemisinin suppositories and oral quinine in children with acute falciparum malaria.

Authors:  T T Hien; D T Tam; N T Cuc; K Arnold
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Mar-Apr       Impact factor: 2.184

2.  Treatment of malaria in Vietnam with oral artemisinin.

Authors:  D S Nguyen; B H Dao; P D Nguyen; V H Nguyen; N B Le; V S Mai; S R Meshnick
Journal:  Am J Trop Med Hyg       Date:  1993-03       Impact factor: 2.345

3.  Antimalarial drug resistance and combination chemotherapy.

Authors:  N White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

4.  A randomized comparative study of artemisinine (qinghaosu) suppositories and oral quinine in acute falciparum malaria.

Authors:  K Arnold; T H Tran; T C Nguyen; H P Nguyen; P Pham
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Jul-Aug       Impact factor: 2.184

5.  Emergence of multidrug-resistant Plasmodium falciparum in Thailand: in vitro tracking.

Authors:  C Wongsrichanalai; H K Webster; T Wimonwattrawatee; P Sookto; N Chuanak; K Thimasarn; W H Wernsdorfer
Journal:  Am J Trop Med Hyg       Date:  1992-07       Impact factor: 2.345

6.  Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria.

Authors:  N N Bich; P J De Vries; H Van Thien; T H Phong; L N Hung; T A Eggelte; T K Anh; P A Kager
Journal:  Am J Trop Med Hyg       Date:  1996-10       Impact factor: 2.345

7.  Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.

Authors:  F ter Kuile; N J White; P Holloway; G Pasvol; S Krishna
Journal:  Exp Parasitol       Date:  1993-02       Impact factor: 2.011

8.  Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand.

Authors:  S Pukrittayakamee; W Supanaranond; S Looareesuwan; S Vanijanonta; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 May-Jun       Impact factor: 2.184

9.  The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria.

Authors:  N J White; D Chapman; G Watt
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

10.  Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients.

Authors:  M Hassan Alin; M Ashton; C M Kihamia; G J Mtey; A Björkman
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jan-Feb       Impact factor: 2.184

View more
  11 in total

1.  Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.

Authors:  Grace O Gbotosho; Akintunde Sowunmi; Christian T Happi; Titilope M Okuboyejo
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

4.  Plasmodium falciparum Na+/H+ exchanger (pfnhe-1) genetic polymorphism in Indian Ocean malaria-endemic areas.

Authors:  Valérie Andriantsoanirina; Nimol Khim; Arsene Ratsimbasoa; Benoit Witkowski; Christophe Benedet; Lydie Canier; Christiane Bouchier; Magali Tichit; Rémy Durand; Didier Ménard
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

Review 5.  Global analysis of Plasmodium falciparum Na(+)/H(+) exchanger (pfnhe-1) allele polymorphism and its usefulness as a marker of in vitro resistance to quinine.

Authors:  Didier Ménard; Valérie Andriantsoanirina; Nimol Khim; Arsène Ratsimbasoa; Benoit Witkowski; Christophe Benedet; Lydie Canier; Odile Mercereau-Puijalon; Rémy Durand
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-10-26       Impact factor: 4.077

6.  Polymorphism of Plasmodium falciparum Na(+)/H(+) exchanger is indicative of a low in vitro quinine susceptibility in isolates from Viet Nam.

Authors:  Véronique Sinou; Le Hong Quang; Stéphane Pelleau; Vu Nhu Huong; Nguyen Thu Huong; Le Minh Tai; Lionel Bertaux; Marc Desbordes; Christine Latour; Lai Quang Long; Nguyen Xuan Thanh; Daniel Parzy
Journal:  Malar J       Date:  2011-06-14       Impact factor: 2.979

Review 7.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

8.  Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium.

Authors:  Annemarie R Kreeftmeijer-Vegter; Perry J van Genderen; Leo G Visser; Wouter F W Bierman; Jan Clerinx; Cees K W van Veldhuizen; Peter J de Vries
Journal:  Malar J       Date:  2012-03-31       Impact factor: 2.979

9.  Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial.

Authors:  Hypolite Muhindo Mavoko; Carolyn Nabasumba; Halidou Tinto; Umberto D'Alessandro; Martin Peter Grobusch; Pascal Lutumba; Jean-Pierre Van Geertruyden
Journal:  Trials       Date:  2013-09-23       Impact factor: 2.279

10.  Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria.

Authors:  Annemarie R Kreeftmeijer-Vegter; Mariana de Mendonça Melo; Peter J de Vries; Rob Koelewijn; Jaap J van Hellemond; Perry J J van Genderen
Journal:  Malar J       Date:  2013-03-27       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.